Zynex (OTC:ZYXI) won approval from the China Food & Drug Administration for its NeuroMove stroke recovery device.
The NeuroMove device is designed to increase the functionality of stroke victims by teaching healthy areas of the brain to compensate for damaged areas.
The NeuroMove is “significantly more sensitive than most diagnostic equipment” as it monitors muscle movement and “selects signals from the brain indicating that the patient is attempting to move a certain muscle,” according to a press release.
The device can also be used to treat spinal cord injury patients.
Last year Zynex acquired NeuroDyne and its portfolio of neurological and neuromuscular devices for $420,000.